Related Experiment Video

Updated: Oct 7, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.7K

[Current therapeutic options in Mycosis fungoides and Sézary syndrome]

Jana Dorothea Albrecht1,2, Jan Peter Nicolay3,4,5

  • 1Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Mannheim GmbH, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. jana.albrecht@umm.de.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|January 6, 2022
PubMed

Insights

New targeted therapies are improving treatment for cutaneous T-cell lymphomas (CTCLs), offering encouraging response rates, especially with combination treatments. This review covers current options for mycosis fungoides and Sézary syndrome based on updated German guidelines.

Area of Science:

  • Dermatology
  • Oncology
  • Clinical Medicine

Background:

  • Significant advancements in managing cutaneous T-cell lymphomas (CTCLs) have emerged due to new targeted therapies.
  • While CTCLs lack curative treatments, combination therapies show encouraging response rates.
  • Treatment decisions for CTCLs are individualized based on diagnosis, stage, and prior treatments.

Purpose of the Study:

  • To provide a comprehensive overview of current treatment options for mycosis fungoides and Sézary syndrome.
  • To align with the revised German S2k guidelines on cutaneous lymphomas (2021 update).
  • To discuss promising, not-yet-approved therapies available off-label.

Main Methods:

  • Review of current treatment options for mycosis fungoides and Sézary syndrome.
  • Analysis based on the German S2k guidelines for cutaneous lymphomas (2021 update).
  • Inclusion of emerging and off-label therapies.

Main Results:

  • Current treatment strategies for CTCLs, particularly mycosis fungoides and Sézary syndrome, are detailed.
  • The efficacy of combination therapies in achieving encouraging response rates is highlighted.
  • Emerging therapies show promise for clinical application, including off-label use.

Conclusions:

  • The management of CTCLs has progressed significantly with targeted therapies.
  • Individualized treatment approaches remain crucial for mycosis fungoides and Sézary syndrome.
  • Future therapeutic options, including off-label use, offer new hope for CTCL patients.
Keywords:
Clinical decision-makingCutaneous T‑cell lymphomaOff-label useResponse rateTargeted therapy

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
719
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K